COGT
Income statement / Annual
Last year (2023), Cogent Biosciences, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Cogent Biosciences, Inc.'s net income was -$192.41 M.
See Cogent Biosciences, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$7.87 M
|
$22.50 M
|
$9.73 M
|
$8.36 M
|
$6.36 M
|
$2.99 M
|
| Cost of Revenue |
$3.59 M |
$5.88 M |
$147,000.00 |
$25,738.00 |
$43,709.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$3.59 M |
-$5.88 M |
-$147,000.00 |
$7.85 M |
$22.46 M |
$9.73 M |
$8.36 M |
$6.36 M |
$2.99 M |
| Gross Profit Ratio |
0 |
0 |
0 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$173.76 M
|
$121.63 M
|
$55.91 M
|
$72.65 M
|
$43.71 M
|
$38.29 M
|
$29.83 M
|
$21.99 M
|
$6.85 M
|
| General & Administrative
Expenses |
$34.38 M
|
$26.21 M
|
$19.64 M
|
$17.42 M
|
$10.97 M
|
$7.45 M
|
$4.68 M
|
$3.43 M
|
$2.73 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$34.38 M
|
$26.21 M
|
$19.64 M
|
$17.42 M
|
$10.97 M
|
$7.45 M
|
$4.68 M
|
$3.43 M
|
$2.73 M
|
| Other Expenses |
$0.00 |
$3.61 M |
$2.81 M |
-$246,000.00 |
$78,000.00 |
$320,000.00 |
$274,000.00 |
$681,000.00 |
$0.00 |
| Operating Expenses |
$208.13 M |
$147.84 M |
$75.55 M |
$90.07 M |
$54.68 M |
$45.74 M |
$34.51 M |
$25.43 M |
$9.58 M |
| Cost And Expenses |
$208.13 M |
$147.84 M |
$75.55 M |
$90.07 M |
$54.68 M |
$45.74 M |
$34.51 M |
$25.43 M |
$9.58 M |
| Interest Income |
$13.08 M |
$3.99 M |
$467,000.00 |
$144,000.00 |
$267,000.00 |
$1.15 M |
$386,000.00 |
$265,000.00 |
$0.00 |
| Interest Expense |
$0.00 |
$3.99 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$2.27 M
|
$5.88 M
|
$147,000.00
|
$720,000.00
|
$1.29 M
|
$1.32 M
|
$1.17 M
|
$830,000.00
|
$179,000.00
|
| EBITDA |
-$205.86 M
|
-$134.36 M
|
-$75.40 M
|
-$34.57 M
|
-$30.89 M
|
-$34.68 M
|
-$24.98 M
|
-$18.24 M
|
-$6.41 M
|
| EBITDA Ratio |
0 |
0 |
0 |
-11.4 |
-1.43 |
-3.56 |
-2.99 |
-2.87 |
-2.15 |
| Operating Income Ratio
|
0
|
0
|
0
|
-10.44
|
-1.43
|
-3.7
|
-3.13
|
-3
|
-2.21
|
| Total Other
Income/Expenses Net |
$15.72 M
|
$7.60 M
|
$3.28 M
|
$7.39 M
|
$345,000.00
|
$1.47 M
|
$660,000.00
|
$946,000.00
|
$0.00
|
| Income Before Tax |
-$192.41 M |
-$140.24 M |
-$72.27 M |
-$74.81 M |
-$31.83 M |
-$34.53 M |
-$25.49 M |
-$18.12 M |
-$6.59 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
-9.5
|
-1.41
|
-3.55
|
-3.05
|
-2.85
|
-2.21
|
| Income Tax Expense |
$0.00 |
-$7.60 M |
-$467,000.00 |
-$8.36 M |
-$1.56 M |
$1.47 M |
-$386,000.00 |
-$265,000.00 |
$0.00 |
| Net Income |
-$192.41 M |
-$132.64 M |
-$71.81 M |
-$66.45 M |
-$30.27 M |
-$34.53 M |
-$25.49 M |
-$18.12 M |
-$6.59 M |
| Net Income Ratio |
0 |
0 |
0 |
-8.44 |
-1.35 |
-3.55 |
-3.05 |
-2.85 |
-2.21 |
| EPS |
-2.42 |
-2.26 |
-1.85 |
-6 |
-3.97 |
-5.55 |
-3.45 |
-3.1 |
-1.13 |
| EPS Diluted |
-2.42 |
-2.26 |
-1.85 |
-6 |
-3.97 |
-5.55 |
-3.45 |
-2.45 |
-0.89 |
| Weighted Average Shares
Out |
$79.66 M
|
$58.74 M
|
$38.73 M
|
$11.08 M
|
$7.62 M
|
$6.22 M
|
$7.40 M
|
$5.86 M
|
$5.86 M
|
| Weighted Average Shares
Out Diluted |
$79.66 M
|
$58.74 M
|
$38.73 M
|
$11.08 M
|
$7.62 M
|
$6.22 M
|
$7.40 M
|
$7.40 M
|
$7.40 M
|
| Link |
|
|
|
|
|
|
|
|
|
